Boussamet, Léo
Montassier, Emmanuel
Mathé, Camille
Garcia, Alexandra
Morille, Jérémy
Shah, Sita
Dugast, Emilie
Wiertlewski, Sandrine
Gourdel, Mathilde
Bang, Corinna
Stürner, Klarissa H.
Masson, Damien
Nicot, Arnaud B.
Vince, Nicolas
Laplaud, David-Axel
Feinstein, Douglas L.
Berthelot, Laureline
Funding for this research was provided by:
Notresclérose
Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques
Conseil Régional des Pays de la Loire (LOIRE-TIMES)
U.S. Department of Veterans Affairs (I01BX002625)
Article History
Received: 4 October 2023
Accepted: 23 March 2024
First Online: 2 April 2024
Competing interests
: E. Montassier received consulting fees from Sanofi, MSD, BMS. DA Laplaud received consulting fees and board membership fees from Alexion, Actelion, BMS, Biogen, Genzyme, Sanofi, Merck-Serono, Novartis, Roche. S. Wiertlewski received consulting and board membership fees Biogen, Genzyme, Novartis, Merck-Serono, Alexion Pharma, Roche, Sanofi. DL Feinstein has a provisional patent filed USPTO application # US 17/715,187. The work was supported in part by Research Career Scientist grant # 14S-RCS-003 from the US Department of Veterans Affairs (DL Feinstein). L Boussamet, L Berthelot, C Mathe, A Garcia, E Dugast, S Shah, J Morille, AB Nicot, N Vince, M Gourdel, D Masson, C Bang and K Sturner do not have competing interest.